Skip to content
value.today
Anika Therapeutics, Inc. logo

Anika Therapeutics, Inc.

ANIK
$267 Mmarket cap on Sep 30, 2026-19.3% since Jan 2024
Compare
World rank
#15,212
Revenue
$113 M
For year ending December-2025
Net income
$-11 M
-9.6% margin
SEC filing
Employees
297
As on 2021
value.today research

Anika Therapeutics, Inc. in brief

Anika Therapeutics, Inc. is a listed company in the Biotechnology industry, based in Bedford, Massachusetts, USA. Its market value was $267 M on 30 September 2026, which makes it the 15,212th largest listed company in the world and the 2,963rd largest in the USA on this site. In the year to December 2025 it had sales of $113 M and a net loss of $11 M. It employs about 297 people and Stephen D. Griffin is its chief executive. Its largest product and service lines by sales in 2025 were OEM Channel (57%) and Commercial Channel (43%). By market, the largest shares of its 2025 sales came from USA (62%) and Europe (20%). Its shares trade under the symbol ANIK (Nasdaq).

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

About Anika Therapeutics, Inc.

Anika offers a broad spectrum of therapeutic treatments ranging from osteoarthritis pain management to joint preservation and restoration. Its proprietary technology is based on hyaluronic acid (HA), a naturally occurring polymer found throughout the body vital for proper joint health and tissue function.

Anika Therapeutics, Inc. timeline

4 events, 1996–2021
  1. 1996
  2. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  3. ✎
    Renamed Anika Therapeutics Inc
    Formerly Anika Research Inc.
  4. 2019
  5. 💰
    Record net income of $27 million
    FY2019, the highest profit of the 3 years on record.
  6. 2021
  7. 💰
    Record revenue of $148 million
    FY2021, the highest of the 8 years on record.

Events of Anika Therapeutics, Inc. from SEC EDGAR and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

$0 M$200 M$399 M$599 M$798 M2020202120222023202420252026

World rank over time

▼ down 6,271 places since 2020
2020-01-01: #9037#9,03720202021-01-01: #9945#9,94520212022-01-07: #13435#13,43520222022-12-25: #13755#13,75520222023-07-30: #14876#14,87620232024-01-05: #15163#15,16320242026-03-08: #9073#9,07320262026-08-01: #14339#14,33920262026-09-30: #15308#15,3082026

Rank in USA: #2,185 (Jan 2020) · #2,552 (Jan 2021) · #3,269 (Jan 2022) · #2,820 (Dec 2022) · #3,018 (Jul 2023) · #2,844 (Jan 2024) · #1,728 (Mar 2026) · #2,895 (Aug 2026) · #2,962 (Sep 2026)

Key ratios

market cap and latest results · TTM = trailing 12 months
P/E ratio (TTM)
n/m (loss)
Price / sales (TTM)
2.2×
Price / book
1.9×
Free cash flow yield
1.6%
Net margin (TTM)
-1.4%
Operating margin
-9.8%
Return on equity
-1.2%
Liabilities / assets
24.6%
Net debt
$-157M
Revenue growth
-5.9%
R&D / revenue
22.8%
Revenue per employee
$380 K
Profit per employee
$-37 K

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Dec 2018: revenue $106M, net income $19M$106MFY18Fiscal year ending Dec 2019: revenue $115M, net income $27M$115MFY19Fiscal year ending Dec 2020: revenue $130M, net income $-24M$130MFY20Fiscal year ending Dec 2021: revenue $148M, net income $4M$148MFY21Fiscal year ending Dec 2022: revenue $114M, net income $-15M$114MFY22Fiscal year ending Dec 2023: revenue $121M, net income $-83M$121MFY23Fiscal year ending Dec 2024: revenue $120M, net income $-56M$120MFY24Fiscal year ending Dec 2025: revenue $113M, net income $-11M$113MFY25
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2025$113M-5.9%$-11M$-11M-9.6%
Dec 2024$120M-0.7%$-5M$-56M-47.0%
Dec 2023$121M+6.1%$1M$-83M-68.4%
Dec 2022$114M-23.0%$4M$-15M-13.1%
Dec 2021$148M+13.3%$3M$4M2.8%
Dec 2020$130M+13.8%$-28M$-24M-18.4%
Dec 2019$115M+8.6%$34M$27M23.7%
Dec 2018$106M—$22M$19M17.7%

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2025$11M$7M$4M$-0.76—
Dec 2024$5M$8M$-2M$-3.83—
Dec 2023$-2M$5M$-7M$-5.64—
Dec 2022$4M$7M$-3M$-1.02—
Dec 2021$8M$5M$3M$0.28—
Dec 2020$13M$2M$11M$-1.69—
Dec 2019$37M$3M$34M$1.89—
Dec 2018$35M$5M$30M$1.27—

Quarterly results

USD · three months to · source: SEC filings
Revenue, trailing 12 months
$123M
Net income, trailing 12 months
$-2M
RevenueNet income
Three months to Dec 2024 (from the annual report): revenue $31M, net income $-22M$31MDec ’24Three months to Mar 2025: revenue $26M, net income $-5M$26MMar ’25Three months to Jun 2025: revenue $28M, net income $-4M$28MJun ’25Three months to Sep 2025: revenue $28M, net income $-2M$28MSep ’25Three months to Dec 2025 (from the annual report): revenue $31M, net income $0M$31MDec ’25Three months to Mar 2026: revenue $30M, net income $-5M$30MMar ’26Three months to Jun 2026: revenue $33M, net income $3M$33MJun ’26Three months to Sep 2026: revenue $31M, net income $-0M$31MSep ’26

Latest quarter to Sep 2026: revenue $31M (+10.0% on a year earlier), net income $-0M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.

SEC filings

Official filings of Anika Therapeutics, Inc. with the US Securities and Exchange Commission.

Annual results

Revenue
$113 M
Operating income
$-11 M
Net income
$-11 M

For year ending December-2025 · source: SEC filing

Balance sheet

Total assets
$190 M
Total liabilities
$47 M
Total equity
$143 M

As of December-2025

Top 100 institutional investors in Anika Therapeutics, Inc.#

As of Sep 30, 2026
139 institutions held 12.1 M shares (about 90.2% of the shares outstanding) on Sep 30, 2026. The ten largest hold 51.6%. Source: SEC Form 13F filings, filed through Nov 17, 2026. Change is since the previous quarter.This quarter is still being filed: about 99% of the institutions that reported last quarter have filed so far. Institutions that have not filed yet are missing from the list, not sellers; the list is brought up to date every day.
The 25 largest institutional investors in Anika Therapeutics, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
1Caligan Partners LP1,435,1300 (0.00%)10.71%$28 MNov 16, 2026
2BlackRock, Inc.1,411,066-38,605 (-2.66%)10.53%$28 MNov 13, 2026
3Morgan Stanley626,369+12,049 (+1.96%)4.68%$12 MNov 13, 2026
4Acadian Asset Management LLC606,5440 (0.00%)4.53%$12 MNov 9, 2026
5Vanguard Capital Management LLC565,908-6,205 (-1.08%)4.22%$11 MNov 13, 2026
6Boothbay Fund Management, LLC529,626-14 (0.00%)3.95%$10 MNov 16, 2026
7Dimensional Fund Advisors LP461,864+10,769 (+2.39%)3.45%$9 MNov 4, 2026
8Renaissance Technologies LLC458,717-22,700 (-4.72%)3.42%$9 MNov 12, 2026
9Geode Capital Management, LLC419,172+87,595 (+26.42%)3.13%$8 MNov 6, 2026
10AQR Capital Management LLC400,986-158,860 (-28.38%)2.99%$8 MNov 16, 2026
11Capital Management Corp /va379,436-69,038 (-15.39%)2.83%$7 MOct 29, 2026
12Deutsche Bank AG\352,134-1,418 (-0.40%)2.63%$7 MNov 6, 2026
13State Street Corp309,452-2,444 (-0.78%)2.31%$6 MNov 12, 2026
14Arrowstreet Capital, Limited Partnership255,568+148,924 (+139.65%)1.91%$5 MNov 13, 2026
15Goldman Sachs Group Inc242,404+4,682 (+1.97%)1.81%$5 MNov 16, 2026
16D. E. Shaw & Co., Inc.217,586-27,480 (-11.21%)1.62%$4 MNov 16, 2026
17Two Sigma Investments, LP214,854-38,110 (-15.07%)1.60%$4 MNov 16, 2026
18Nuveen, LLC166,522+9,984 (+6.38%)1.24%$3 MNov 10, 2026
19Quantinno Capital Management LP155,337+80 (+0.05%)1.16%$3 MNov 13, 2026
20Hillsdale Investment Management Inc.155,221+16,400 (+11.81%)1.16%$3 MNov 12, 2026
21Jacobs Levy Equity Management, Inc153,285-64,245 (-29.53%)1.14%$3 MNov 16, 2026
22Globeflex Capital L P139,103+51,503 (+58.79%)1.04%$3 MNov 16, 2026
23Qube Research & Technologies Ltd118,076New0.88%$2 MNov 13, 2026
24Charles Schwab Investment Management Inc117,414+4,040 (+3.56%)0.88%$2 MNov 16, 2026
25Northern Trust Corp94,794-3,340 (-3.40%)0.71%$2 MNov 16, 2026
Show all 100: investors 26 to 100
Institutional investors 26 to 100 in Anika Therapeutics, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
26Vanguard Fiduciary Trust Co87,537+10 (+0.01%)0.65%$2 MNov 13, 2026
27UBS Group AG87,107-58,709 (-40.26%)0.65%$2 MNov 10, 2026
28Prudential Financial Inc84,245+72,935 (+644.87%)0.63%$2 MNov 16, 2026
29Vanguard Portfolio Management LLC78,365+1,592 (+2.07%)0.58%$2 MNov 13, 2026
30Envestnet Asset Management Inc71,362-17,393 (-19.60%)0.53%$1 MNov 16, 2026
31Massachusetts Financial Services Co /ma/68,653-3,105 (-4.33%)0.51%$1 MNov 12, 2026
32Ironwood Investment Management LLC65,744+241 (+0.37%)0.49%$1 MNov 12, 2026
33BNP Paribas Financial Markets58,118-5,835 (-9.12%)0.43%$1 MNov 12, 2026
34FMR LLC57,619+4,639 (+8.76%)0.43%$1 MNov 10, 2026
35Barclays PLC54,333+2,014 (+3.85%)0.41%$1 MNov 6, 2026
36Diker Management LLC51,662-2,000 (-3.73%)0.39%$1 MNov 16, 2026
37HSBC Holdings PLC51,628+1,523 (+3.04%)0.39%$1 MNov 16, 2026
38Jpmorgan Chase & Co49,112-5,103 (-9.41%)0.37%$1 MNov 12, 2026
39Ameriprise Financial Inc45,900-6,455 (-12.33%)0.34%$1 MNov 16, 2026
40Palumbo Wealth Management LLC44,656+4,580 (+11.43%)0.33%$1 MNov 13, 2026
41Indivisible Partners43,019-3,235 (-6.99%)0.32%$1 MOct 26, 2026
42Advyzon Investment Management, LLC42,414-3,208 (-7.03%)0.32%$1 MNov 16, 2026
43Lazard Asset Management LLC41,973New0.31%$1 MNov 16, 2026
44Assenagon Asset Management S.A.40,376-85,656 (-67.96%)0.30%$1 MOct 15, 2026
45Cerity Partners LLC40,083-579 (-1.42%)0.30%$1 MNov 13, 2026
46Bank of New York Mellon Corp39,337+564 (+1.45%)0.29%$1 MNov 5, 2026
47Bank Of America Corp /de/37,298+12,750 (+51.94%)0.28%$1 MNov 16, 2026
48Invesco Ltd.36,062+5,549 (+18.19%)0.27%$1 MNov 12, 2026
49Corient Private Wealth LP34,020-1,395 (-3.94%)0.25%$1 MNov 16, 2026
50Tudor Investment Corp Et Al33,683+10,846 (+47.49%)0.25%$1 MNov 16, 2026
51Marshall Wace, LLP31,197+9,279 (+42.34%)0.23%$1 MNov 13, 2026
52Man Group plc31,118-109,594 (-77.89%)0.23%$1 MNov 16, 2026
53State Of Wisconsin Investment Board30,342-3,558 (-10.50%)0.23%$1 MNov 16, 2026
54Strs Ohio29,700+10,500 (+54.69%)0.22%$1 MOct 30, 2026
55Ieq Capital, LLC29,651-3,815 (-11.40%)0.22%$1 MNov 10, 2026
56American Century Companies Inc29,470-74,089 (-71.54%)0.22%$1 MNov 12, 2026
57Mercer Global Advisors Inc /adv29,118+3,833 (+15.16%)0.22%$1 MNov 16, 2026
58Bridgeway Capital Management, LLC25,208+7,708 (+44.05%)0.19%$0 MNov 16, 2026
59Quadrature Capital Ltd24,135New0.18%$0 MNov 13, 2026
60R Squared Ltd24,019-3,046 (-11.25%)0.18%$0 MNov 6, 2026
61Point72 Asset Management, L.P.23,139+624 (+2.77%)0.17%$0 MNov 16, 2026
62Mariner, LLC23,024-2,932 (-11.30%)0.17%$0 MNov 12, 2026
63Martingale Asset Management L P23,014+7,702 (+50.30%)0.17%$0 MNov 12, 2026
64Gsa Capital Partners LLP22,148-4,035 (-15.41%)0.17%$0 MNov 16, 2026
65Citadel Advisors LLC21,792New0.16%$0 MNov 16, 2026
66Alliancebernstein L.P.20,850-1,060 (-4.84%)0.16%$0 MNov 16, 2026
67Segall Bryant & Hamill, LLC19,877New0.15%$0 MNov 16, 2026
68Blueprint Investment Partners LLC17,646New0.13%$0 MOct 28, 2026
69Blueprint Financial Advisors LLC17,646New0.13%$0 MOct 28, 2026
70Millennium Management LLC17,210+2,773 (+19.21%)0.13%$0 MNov 16, 2026
71Empowered Funds, LLC17,208New0.13%$0 MNov 13, 2026
72Northwest & Ethical Investments L.P.16,389New0.12%$0 MNov 12, 2026
73Rhumbline Advisers15,611-733 (-4.48%)0.12%$0 MNov 10, 2026
74Integrated Quantitative Investments LLC15,540-3,539 (-18.55%)0.12%$0 MNov 13, 2026
75Bailard, Inc.15,526New0.12%$0 MOct 13, 2026
76Wealth Enhancement Advisory Services, LLC15,476-101 (-0.65%)0.12%$0 MOct 13, 2026
77Simplicity Wealth,LLC14,500New0.11%$0 MOct 23, 2026
78Canada Pension Plan Investment Board13,000-9,000 (-40.91%)0.10%$0 MNov 16, 2026
79Los Angeles Capital Management LLC12,900+12,800 (+12800.00%)0.10%$0 MNov 12, 2026
80XTX Topco Ltd12,830-5,044 (-28.22%)0.10%$0 MNov 16, 2026
81Noesis Capital Mangement Corp11,740-7,660 (-39.48%)0.09%$0 MOct 26, 2026
82Squarepoint Ops LLC11,304-7,447 (-39.72%)0.08%$0 MNov 9, 2026
83Kemnay Advisory Services Inc.10,450+2,492 (+31.31%)0.08%$0 MNov 16, 2026
84Connor, Clark & Lunn Investment Management Ltd.10,389New0.08%$0 MNov 10, 2026
85Russell Investments Group, Ltd.10,282+1,873 (+22.27%)0.08%$0 MNov 6, 2026
86MetLife Investment Management, LLC7,1220 (0.00%)0.05%$0 MNov 16, 2026
87Arax Advisory Partners6,010+436 (+7.82%)0.04%$0 MNov 12, 2026
88Vanguard Global Advisers, LLC5,816+1,497 (+34.66%)0.04%$0 MNov 13, 2026
89MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.5,472+200 (+3.79%)0.04%$0 MNov 16, 2026
90Citigroup Inc3,670-1,608 (-30.47%)0.03%$0 MNov 4, 2026
91Versant Capital Management, Inc3,446-287 (-7.69%)0.03%$0 MOct 2, 2026
92New York State Common Retirement Fund3,4230 (0.00%)0.03%$0 MNov 17, 2026
93Police & Firemen's Retirement System of New Jersey3,2620 (0.00%)0.02%$0 MNov 9, 2026
94Public Employees Retirement System Of Ohio2,910-16,065 (-84.66%)0.02%$0 MNov 16, 2026
95Meeder Asset Management Inc2,736+240 (+9.62%)0.02%$0 MNov 10, 2026
96Wells Fargo & Company/mn2,294-7,362 (-76.24%)0.02%$0 MNov 16, 2026
97PNC Financial Services Group, Inc.1,557+66 (+4.43%)0.01%$0 MNov 6, 2026
98Ameritas Investment Partners, Inc.1,2020 (0.00%)0.01%$0 MNov 13, 2026
99Allworth Financial LP1,102+111 (+11.20%)0.01%$0 MNov 17, 2026
100Legal & General Group Plc1,0810 (0.00%)0.01%$0 MNov 16, 2026

All 139 institutional investors, with who bought and sold →

Mutual funds holding Anika Therapeutics, Inc.#

141 funds hold shares worth $41 M (about 19.4% of the company). Since their previous reports 44 added shares and 37 sold, selling $0 M net.
Mutual funds holding Anika Therapeutics, Inc.
FundSharesValueOf the companyOf the fundChange in sharesReport
🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc.397,824$6 M3.0%<0.01%−7.2%Jun 30, 2026
🇺🇸 iShares Russell 2000 ETFBlackRock Fund Advisors311,291$5 M2.3%<0.01%+1.8%Jun 30, 2026
🇺🇸 Fidelity Small Cap Index FundFidelity Management & Research Company LLC123,749$2 M0.92%<0.01%+1.8%Jul 31, 2026
🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc.162,458$2 M1.2%<0.01%−0.4%Jun 30, 2026
🇺🇸 College Retirement Equities Fund - Total Global Stock AccountTIAA-CREF Investment Management, LLC142,287$2 M1.1%<0.01%+71%Jun 30, 2026
🇺🇸 U.S. Small Cap Value PortfolioDimensional Fund Advisors LP86,697$2 M0.65%<0.01%+53%Jul 31, 2026
🇺🇸 iShares Russell 2000 Value ETFBlackRock Fund Advisors104,916$2 M0.78%0.01%+0.2%Jun 30, 2026
🇺🇸 Avantis U.S. Small Cap Value ETFAmerican Century ETF Trust101,973$1 M0.76%<0.01%+6.0%May 31, 2026
🇺🇸 U.S. Small Cap PortfolioDimensional Fund Advisors LP61,098$1 M0.46%<0.01%no changeJul 31, 2026
🇺🇸 Dimensional US Small Cap Value ETFDimensional Fund Advisors LP56,771$1 M0.42%0.01%+38%Jul 31, 2026
🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC73,771$1 M0.55%<0.01%−4.4%May 31, 2026
🇺🇸 Schwab U.S. Small-Cap ETFCharles Schwab Investment Management, Inc.66,746$1 M0.50%<0.01%−1.3%May 31, 2026
🇺🇸 U.S. Micro Cap PortfolioDimensional Fund Advisors LP49,285$1 M0.37%0.01%no changeJul 31, 2026
🇺🇸 Vanguard Russell 2000 Index FundThe Vanguard Group, Inc.64,319$1 M0.48%<0.01%+4.5%May 31, 2026
🇺🇸 Dimensional U.S. Small Cap ETFDimensional Fund Advisors LP41,182$1 M0.31%<0.01%−6.2%Jul 31, 2026
🇺🇸 MFS Blended Research Small Cap Equity FundMASSACHUSETTS FINANCIAL SERVICES COMPANY48,172$1 M0.36%0.21%−3.7%May 31, 2026
🇺🇸 iShares Micro-Cap ETFBlackRock Fund Advisors38,472$1 M0.29%0.04%+23%Jun 30, 2026
🇺🇸 Schwab Small-Cap Index FundCharles Schwab Investment Management, Inc.27,027$1 M0.20%<0.01%+0.2%Jul 31, 2026
🇺🇸 Multi-Manager Small Cap Equity Strategies FundColumbia Funds Series Trust I35,515$1 M0.27%0.04%no changeMay 31, 2026
🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC26,302$0 M0.20%<0.01%no changeMay 31, 2026
🇺🇸 Avantis U.S. Small Cap Equity ETFAmerican Century ETF Trust24,030$0 M0.18%0.01%−11%May 31, 2026
🇺🇸 Master Small Cap Index SeriesBlackRock Advisors, LLC22,850$0 M0.17%<0.01%no changeJun 30, 2026
🇺🇸 NVIT Multi-Manager Small Company FundNATIONWIDE FUND ADVISORS22,292$0 M0.17%0.07%no changeJun 30, 2026
🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC21,446$0 M0.16%<0.01%+6.9%May 31, 2026
🇺🇸 NVIT Small Cap Value FundNATIONWIDE FUND ADVISORS20,885$0 M0.16%0.14%−3.2%Jun 30, 2026
🇺🇸 Invesco RAFI US 1500 Small-Mid ETFInvesco Capital Management LLC15,448$0 M0.12%0.01%+3.7%Jul 31, 2026
🇺🇸 VIP Disciplined Small Cap PortfolioFidelity Management & Research Company LLC18,236$0 M0.14%0.04%+47%Jun 30, 2026
🇺🇸 U.S. Core Equity 2 PortfolioDimensional Fund Advisors LP13,792$0 M0.10%<0.01%no changeJul 31, 2026
🇺🇸 Ultra-Small Company Market FundBridgeway Capital Management, LLC17,500$0 M0.13%0.17%no changeJun 30, 2026
🇺🇸 U.S. Targeted Value PortfolioDimensional Fund Advisors LP12,107$0 M0.09%<0.01%−80%Jul 31, 2026
🇺🇸 Fidelity Small Cap Value Index FundFidelity Management & Research Company LLC15,789$0 M0.12%0.01%+4.5%Jun 30, 2026
🇺🇸 U.S. Vector Equity PortfolioDimensional Fund Advisors LP11,894$0 M0.09%<0.01%no changeJul 31, 2026
🇺🇸 U.S. Core Equity 1 PortfolioDimensional Fund Advisors LP11,355$0 M0.08%<0.01%no changeJul 31, 2026
🇺🇸 Small Cap Equity FundGuideStone Capital Management, LLC14,782$0 M0.11%0.02%−40%Jun 30, 2026
🇺🇸 Nuveen Equity Index FundTeachers Advisors, LLC11,088$0 M0.08%<0.01%no changeJul 31, 2026
🇺🇸 Goldman Sachs ActiveBeta U.S. Small Cap Equity ETFGoldman Sachs Asset Management, L.P.13,535$0 M0.10%0.02%+1.3%May 31, 2026
🇺🇸 Nuveen Small Cap Blend Index FundTeachers Advisors, LLC10,042$0 M0.07%<0.01%−45%Jul 31, 2026
🇺🇸 PGIM Quant Solutions Small-Cap Value FundPGIM INVESTMENTS LLC10,000$0 M0.07%0.04%newJul 31, 2026
🇺🇸 Schwab Total Stock Market Index FundCharles Schwab Investment Management, Inc.10,000$0 M0.07%<0.01%no changeJul 31, 2026
🇺🇸 EQ/Small Company Index PortfolioEquitable Investment Management Group, LLC12,430$0 M0.09%<0.01%+6.2%Jun 30, 2026
🇺🇸 EQ/2000 Managed Volatility PortfolioEquitable Investment Management Group, LLC11,614$0 M0.09%<0.01%no changeJun 30, 2026
🇺🇸 Fidelity ZERO Total Market Index FundFidelity Management & Research Company LLC7,602$0 M0.06%<0.01%+12%Jul 31, 2026
🇺🇸 Dimensional U.S. Targeted Value ETFDimensional Fund Advisors LP7,426$0 M0.06%<0.01%−74%Jul 31, 2026
🇺🇸 Vanguard Russell 2000 Value Index FundThe Vanguard Group, Inc.9,661$0 M0.07%0.01%+8.8%May 31, 2026
🇺🇸 LVIP State Street Small-Cap Index FundLincoln Financial Investments Corporation9,395$0 M0.07%<0.01%no changeJun 30, 2026
🇺🇸 Schwab U.S. Broad Market ETFCharles Schwab Investment Management, Inc.8,500$0 M0.06%<0.01%no changeMay 31, 2026
🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC8,165$0 M0.06%<0.01%−25%May 31, 2026
🇺🇸 EQ/AB Small Cap Growth PortfolioEquitable Investment Management Group, LLC7,980$0 M0.06%<0.01%+10%Jun 30, 2026
🇺🇸 Dimensional U.S. Marketwide Value ETFDimensional Fund Advisors LP6,027$0 M0.04%<0.01%no changeJul 31, 2026
🇺🇸 Goldman Sachs Absolute Return Tracker FundGoldman Sachs Asset Management, L.P.7,493$0 M0.06%<0.01%−11%Jun 30, 2026
🇺🇸 U.S. Sustainability Core 1 PortfolioDimensional Fund Advisors LP5,680$0 M0.04%<0.01%no changeJul 31, 2026
🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc.7,261$0 M0.05%<0.01%−24%Jun 30, 2026
🇺🇸 JPMorgan Diversified Return U.S. Small Cap Equity ETFJ.P. Morgan Investment Management Inc.5,502$0 M0.04%0.02%+15%Jul 31, 2026
🇺🇸 Global X Russell 2000 ETFGlobal X Management Company LLC5,460$0 M0.04%<0.01%+0.9%Jul 31, 2026
🇺🇸 Diversified Equity Alpha Master PortfolioBlackRock Fund Advisors6,693$0 M0.05%<0.01%−23%Jun 30, 2026
🇺🇸 Fidelity ZERO Extended Market Index FundFidelity Management & Research Company LLC4,935$0 M0.04%<0.01%−4.3%Jul 31, 2026
🇺🇸 iShares Russell 3000 ETFBlackRock Fund Advisors6,026$0 M0.04%<0.01%−0.8%Jun 30, 2026
🇺🇸 Small Cap Index FundNorthern Trust Investments, Inc.5,800$0 M0.04%<0.01%−13%Jun 30, 2026
🇺🇸 Dimensional VA U.S. Targeted Value PortfolioDimensional Fund Advisors LP4,287$0 M0.03%<0.01%−16%Jul 31, 2026
🇺🇸 Venerable US Small Cap FundVenerable Investment Advisers, LLC5,244$0 M0.04%0.05%−2.9%Jun 30, 2026
🇺🇸 Bridge Builder Small/Mid Cap Value FundOLIVE STREET INVESTMENT ADVISERS LLC5,191$0 M0.04%<0.01%no changeJun 30, 2026
🇺🇸 State Street Small/mid Cap Equity Index PortfolioSSGA Funds Management, Inc.5,047$0 M0.04%<0.01%+28%Jun 30, 2026
🇺🇸 Small Cap Index FundThe Variable Annuity Life Insurance Company5,068$0 M0.04%<0.01%no changeMay 31, 2026
🇺🇸 AQR Small Cap Multi-Style FundAQR CAPITAL MANAGEMENT, LLC4,683$0 M0.03%0.02%newJun 30, 2026
🇺🇸 Vanguard Institutional Total Stock Market Index FundThe Vanguard Group, Inc.4,570$0 M0.03%<0.01%no changeJun 30, 2026
🇺🇸 MetLife Russell 2000 Index PortfolioBrighthouse Investment Advisers, LLC4,117$0 M0.03%<0.01%no changeJun 30, 2026
🇺🇸 JNL/DFA U.S. Small Cap FundJackson National Asset Management, LLC3,758$0 M0.03%<0.01%no changeJun 30, 2026
🇺🇸 Small-Cap Index PortfolioPacific Life Fund Advisors LLC3,621$0 M0.03%<0.01%no changeJun 30, 2026
🇺🇸 ATM Small Cap Managed Volatility PortfolioEquitable Investment Management Group, LLC3,552$0 M0.03%<0.01%−20%Jun 30, 2026
🇺🇸 Nationwide Fundamental All Cap Equity PortfolioNATIONWIDE FUND ADVISORS2,660$0 M0.02%<0.01%+555%Jul 31, 2026
🇺🇸 Avantis U.S. Equity ETFAmerican Century ETF Trust3,415$0 M0.03%<0.01%no changeMay 31, 2026
🇺🇸 Siit Extended Market Index FundSEI INVESTMENTS MANAGEMENT CORPORATION3,070$0 M0.02%<0.01%no changeMay 31, 2026
🇺🇸 Avantis U.S. Small Cap Value FundAmerican Century ETF Trust2,971$0 M0.02%<0.01%no changeMay 31, 2026
🇺🇸 Thrivent Moderately Aggressive Allocation PortfolioThrivent Financial for Lutherans2,953$0 M0.02%<0.01%+52%Jun 30, 2026
🇺🇸 U.S. Social Core Equity 2 PortfolioDimensional Fund Advisors LP2,097$0 M0.02%<0.01%no changeJul 31, 2026
🇺🇸 AST Small-Cap Equity PortfolioAST Investment Services, Inc.2,680$0 M0.02%<0.01%no changeJun 30, 2026
🇺🇸 Thrivent Moderately Aggressive Allocation FundThrivent Asset Management LLC2,032$0 M0.02%<0.01%+52%Jul 31, 2026
🇺🇸 Fidelity Flex Small Cap Index FundFidelity Management & Research Company LLC2,005$0 M0.01%<0.01%−7.4%Jul 31, 2026
🇺🇸 1290 VT Micro Cap PortfolioEquitable Investment Management Group, LLC2,601$0 M0.02%0.02%+19%Jun 30, 2026
🇺🇸 Spectrum FundMeeder Asset Management, Inc.2,496$0 M0.02%0.01%newJun 30, 2026
🇺🇸 Dimensional U.S. Equity Market ETFDimensional Fund Advisors LP1,888$0 M0.01%<0.01%no changeJul 31, 2026
🇺🇸 iShares Russell Small/Mid-Cap Index FundBlackRock Advisors, LLC1,887$0 M0.01%<0.01%no changeJul 31, 2026
🇺🇸 Small Cap Index TrustJohn Hancock Variable Trust Advisers LLC2,483$0 M0.02%<0.01%no changeJun 30, 2026
🇺🇸 Thrivent Moderate Allocation PortfolioThrivent Financial for Lutherans2,447$0 M0.02%<0.01%+52%Jun 30, 2026
🇺🇸 NVIT Small Cap Index FundNATIONWIDE FUND ADVISORS2,320$0 M0.02%<0.01%no changeJun 30, 2026
🇺🇸 Thrivent Aggressive Allocation FundThrivent Asset Management LLC1,522$0 M0.01%<0.01%+51%Jul 31, 2026
🇺🇸 Strategic Advisers U.S. Total Stock FundStrategic Advisers LLC1,992$0 M0.01%<0.01%−55%May 31, 2026
🇺🇸 LVIP Dimensional U.S. Core Equity 1 FundLincoln Financial Investments Corporation1,937$0 M0.01%<0.01%no changeJun 30, 2026
🇺🇸 SA Small Cap Index PortfolioSunAmerica Asset Management, LLC1,467$0 M0.01%<0.01%no changeJul 31, 2026
🇺🇸 1290 VT Small Cap Value PortfolioEquitable Investment Management Group, LLC1,919$0 M0.01%<0.01%no changeJun 30, 2026
🇺🇸 Victory Extended Market Index FundVictory Capital Management Inc.1,455$0 M0.01%<0.01%−1.3%Jul 31, 2026
🇺🇸 Dimensional US Core Equity Market ETFDimensional Fund Advisors LP1,436$0 M0.01%<0.01%no changeJul 31, 2026
🇺🇸 Voya RussellTM Small Cap Index PortfolioVoya Investments, LLC1,889$0 M0.01%<0.01%+32%Jun 30, 2026
🇺🇸 BlackRock Small Cap Index V.I. FundBlackRock Advisors, LLC1,826$0 M0.01%<0.01%no changeJun 30, 2026
🇺🇸 SA U.S. Small Company FundFocus Advisor Solutions, LLC1,795$0 M0.01%<0.01%no changeJun 30, 2026
🇺🇸 T. Rowe Price Small-Cap Index FundT. Rowe Price Associates, Inc.1,783$0 M0.01%<0.01%no changeJun 30, 2026
🇺🇸 DWS Small Cap Index VIPDWS Investment Management Americas, Inc.1,722$0 M0.01%<0.01%no changeJun 30, 2026
🇺🇸 iShares Total U.S. Stock Market Index FundBlackRock Advisors, LLC1,304$0 M<0.01%<0.01%no changeJul 31, 2026
🇺🇸 Small Cap Opportunities TrustJohn Hancock Variable Trust Advisers LLC1,585$0 M0.01%0.01%no changeJun 30, 2026
🇺🇸 Blackstone Alternative Multi-Strategy FundBlackstone Alternative Investment Advisors LLC1,500$0 M0.01%<0.01%no changeJun 30, 2026

Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 100 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.

Insider trading at Anika Therapeutics, Inc.#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$264 K
4 purchases, 3 insiders
Sold, 12 months
$0
0 sales, 0 insiders
Net, 12 months
$264 K
open market only
Insiders on file
35
since
$150 K$0Apr 2026: bought $150 K (1 trades), sold $0 (0 trades)Apr 26May 2026: bought $73 K (1 trades), sold $0 (0 trades)MayAug 2026: bought $41 K (2 trades), sold $0 (0 trades)Aug
Bought (open market)Sold (open market)Hover a month for the totals
Anika Therapeutics, Inc.: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed Gary P. FischettiDirectorBuy+1,000$20.32$20 K54,015Form 4
filed Gary P. FischettiDirectorBuy+1,000$20.75$21 K53,015Form 4
filed John B. Henneman IIIDirectorGrant or award+10,402——65,273Form 4
filed Joseph H. CapperDirectorGrant or award+10,402——30,805Form 4
filed Gary P. FischettiDirectorGrant or award+10,402——52,015Form 4
filed Stephen RichardDirectorGrant or award+10,402——58,273Form 4
filed Sheryl L. ConleyDirectorGrant or award+10,402——52,970Form 4
filed Stephen D. GriffinPresident and CEO, DirectorOption exercise+12,840——49,742Form 4

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals

Markets and events: Anika Therapeutics, Inc.#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Short interest, 2026-10-30
323,508
2.3% of shares · 3.13 days to cover
Buybacks, Q3 2026
$0M
Q3 2026
Shares sold short, last 24 reportsAll stocks →
Anika Therapeutics, Inc. share buybacks by quarter
Buybacks, quarterFiscalSpent
Q3 2026Q3 2026$0M
Q2 2026Q2 2026$0.9M
Q1 2026Q1 2026$8.7M
Q4 2025Q4 2025$5.5M
Q3 2025Q3 2025$0M
Q2 2025Q2 2025$0M
Q1 2025Q1 2025$4M
Q4 2024Q4 2024$5.6M
Q3 2024Q3 2024$4M
Q2 2024Q2 2024$1.4M
Q1 2024Q1 2025$0M
Q4 2023Q4 2023$0M
Q3 2023Q3 2023$0M
Q4 2022Q4 2023$0M
Q3 2022Q3 2023$0M
Q4 2020Q4 2020$0M

Fails to deliver

  • : 55 shares at $19.95
  • : 659 shares at $20.68
  • : 223 shares at $21.42
  • : 15 shares at $19.19
  • : 13 shares at $19.28

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

Anika Therapeutics, Inc. scorecard#

Passes 8 of the 22 checks that could be worked out: strongest in financial health (2 of 3), weakest in growth (1 of 6). Fiscal year 2025; market cap of Sep 30, 2026.

  • Valuation2 of 5
    • ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
    • ✓Price to book below its peers' median1.9×Price to book 1.9× against Biotechnology's median of 2.9×.
    • ✓Price to sales below its peers' median2.2×Price to sales 2.2× against Biotechnology's median of 8.7×.
    • ✗Free cash flow yield above 5%1.6%Free cash flow is 1.6% of the market value.
    • ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
    • –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
  • Growth1 of 6
    • ✗Revenue grew in the newest year-5.9%Revenue down 5.9% in fiscal 2025.
    • ✗Revenue up more than 5% a year over three years-0.3%-0.3% a year over the three years to fiscal 2025.
    • ✗Faster growth over three years than its peers' median-0.3%-0.3% a year against Biotechnology's median of 12.9% (181 companies).
    • ✗Earnings per share grew in the newest year-0.76 vs -3.83Diluted EPS -0.76 in fiscal 2025 against -3.83 the year before (report's currency).
    • ✓Net income higher than five years earlier-$11 M-$11 M in fiscal 2025 against -$24 M in 2020.
    • ✗Revenue rose in at least four of the last five years2 of 5Revenue rose in 2 of the five years to fiscal 2025.
  • Profitability1 of 5
    • ✗Profitable in the newest year-$11 MNet income -$11 M in fiscal 2025.
    • ✗Profitable in each of the last five years1 of 5Profitable in 1 of the five years to fiscal 2025.
    • ✓Operating margin above its peers' median-9.8%-9.8% against Biotechnology's median of -60.5% (243 companies).
    • ✗Return on equity above 15%-7.3%-7.3% in fiscal 2025.
    • –Return on invested capital above 10%No return on invested capital on file.
    • ✗Operating margin wider than three years earlier-9.8%-9.8% in fiscal 2025 against 3.2% in 2022.
  • Financial health2 of 3
    • ✓Short-term assets cover short-term liabilities4.7×Current ratio 4.72 at the end of fiscal 2025.
    • –Debt below equityDebt or equity is not on file (or equity is negative).
    • –Net debt below three years of EBITDANet debt to EBITDA is not on file.
    • –Operating income covers interest five timesInterest expense is not on file.
    • ✗Cash from operations positive in each of the last three years2 of 3Positive in 2 of the three years to fiscal 2025.
    • ✓Altman Z-score outside the distress zone4.79Z-score 4.79 (safe zone) for fiscal 2025.
  • Shareholder returns2 of 3
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • ✓Share count up no more than 2% in a year-2.6%Diluted shares down 2.6% in fiscal 2025.
    • ✓Dividends and buybacks above 3% of the market value3.5%Dividends and buybacks were 3.5% of the market value.
    • ✗Free cash flow covers dividends and buybacks$4 MFree cash flow $4 M against $9 M paid out in fiscal 2025.

Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Financial analysis, 2025#

Worked out from Anika Therapeutics, Inc.'s statements, beside the median of Biotechnology.

Anika Therapeutics, Inc.: main financial ratios in 2025
Ratio2025Median of peers
Operating margin-9.8%-60.5%
Net margin-9.6%-68.9%
Return on equity-7.3%-61.0%
Revenue growth, 3 years a year-0.3%12.9%
Revenue growth-5.9%15.8%
Free cash flow margin3.9%-61.5%

5of 8on the Piotroski tests of financial strength

  • Revenue fell 5.9% against the year before.
  • Net loss of $11 million, the 4th loss-making year in a row.
  • The share count fell 2.6% in the year (buybacks).

Anika Therapeutics, Inc.: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

Anika Therapeutics, Inc.: statements by fiscal year
PeriodTrendFY 2025to Dec 31, 2025FY 2024to Dec 31, 2024FY 2023to Dec 31, 2023FY 2022to Dec 31, 2022FY 2021to Dec 31, 2021FY 2020to Dec 31, 2020FY 2019to Dec 31, 2019FY 2018to Dec 31, 2018FY 2017to Dec 31, 2017FY 2016to Dec 31, 2016
Income statement
Revenue113120121r114r148130115106113103
Cost of revenue494438r41r656129312724
Gross profit647683r73r83698674——
Research and development262622r18r272317181911
Selling, general and administrative495660r51r746035342218
Total costs and expenses758182r70r809752r53r6853
Operating income−11−5.10.8r3.7r2.6−2834224651
Income before tax−9.3−2.83.2r4.3r2.4−2936234651
Income tax0.76.16.6r2.1r−1.7−4.68.94.51418
Income from continuing operations−10.0−8.8−3.42.2——————
Income from discontinued operations−0.9−48−79−17——————
Net income attributable to shareholders−11−56−83−154.1−2427193233
Earnings per share, basic-0.76-3.83-5.64-1.020.29-1.691.931.302.182.22
Earnings per share, diluted-0.76-3.83-5.64-1.020.28-1.691.891.272.112.15
Shares, weighted average (basic)141515151414r14r14r1515
Shares, weighted average (diluted)14151515r1514r14r15r1515
Balance sheet
Cash and cash equivalents575669r86949615789133104
Short-term investments242426r3530r2.527702421
Receivables242426r35302423212428
Inventory192424r40364622212216
Other current assets3.45.57.5r8.88.38.84.31.93.22.1
Current assets103114163170169177234203206170
Property, plant and equipment403937r48485151545652
Right-of-use (leased) assets262628r31212323———
Goodwill8.17.17.67.37.88.47.77.98.27.2
Other intangible assets1.72.52.6r7582917.69.21110
Total assets190203271349348366331279283240
Accounts payable6.05.66.2r9.17.69.03.83.16.72.3
Current liabilities2223312830371611138.8
Long-term debt——————0———
Lease liabilities (non-current)242426r29192121———
Retained earnings6172128211226221245218200168
Shareholders' equity143154212286287272288264263223
Total liabilities and equity190203271349348366331279283240
Shares outstanding14141515141414141515r
Cash-flow statement
Depreciation and amortization5.46.96.46.76.56.1r5.0r5.94.33.7
Share-based compensation10131514115.46.1115.83.4
Cash from operating activities115.4−1.84.48.41337354124r
Capital expenditure−6.8−7.7−5.4−7.5−5.1−1.6−2.8−4.7−9.0−14
Intangible assets bought0−0.600——————
Acquisitions, net of cash acquired——00−0.5−9500——
Cash from investing activities−0.4−8.3−5.4−7.5−3.1−7140−50−12−6.8
Debt issued———005000——
Debt repaid———00−5000——
Shares bought back−9.5−11−5.0000−30−30—−25
Cash from financing activities−11−13−6.3−4.9−6.8−3.8−8.1−290.3−24r
Exchange-rate effect on cash——————−0.10.00.3−0.1
Change in cash0.3−16−13−8.1−1.4−6268−4429−6.4
Report10-K10-K10-K10-K10-K10-K10-K10-K/A10-K10-K

r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

What Anika Therapeutics, Inc. sells: revenue by product line, fiscal 2025#

As the company reports it, in US dollars, with each line's share of total revenue and the change on fiscal 2024. Lines can overlap (a total and its parts), so they are not added up.

Products and services

  • OEM Channel$64 M57%
  • Commercial Channel$48 M43%

Countries and regions

  • 🇺🇸 USA$70 M62%
  • Europe$22 M20%
  • Other Location$21 M18%

Source: SEC annual report (XBRL data) · as of Dec 31, 2025

Executive pay at Anika Therapeutics, Inc.#

From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.

CEO total pay, fiscal 2025
$4.9 M
Stephen D. Griffin
Other top executives, average
$1.3 M
the CEO earned 3.6× this
$100 invested is now
$21
peer group: $120
Anika Therapeutics, Inc.: executive pay by fiscal year
Fiscal yearCEO total payActually paidOther executives, average$100 invested
2025Stephen D. Griffin$4.9 M$2.1 M$1.3 M$21 (peers $120)
2024Stephen D. Griffin$5.1 M$2.5 M$1.8 M$36 (peers $91)
2023Stephen D. Griffin$4.5 M$1.9 M$1.4 M$50 (peers $92)
2022Stephen D. Griffin$5.9 M$3.6 M$1.7 M$65 (peers $89)
2021Stephen D. Griffin$4.2 M$1.8 M$1.2 M$79 (peers $99)

Source: SEC proxy statement (Form DEF 14A) · as of Dec 31, 2025

Events at Anika Therapeutics, Inc.#

What the company reported to the SEC within four business days (Form 8-K), newest first.

No warning signs in the last three years: no bankruptcy, delisting notice, withdrawn financial statements, auditor change, cybersecurity incident, debt called early or impairment was reported.

Acquisition or sale completed 2 · Directors and officers 9 · Material agreement 2 · New debt 1 · Shareholder vote 3 · Results announced 13

Anika Therapeutics, Inc.: events reported to the SEC
FiledWhat happenedFiling
Results announced8-K
Results announced8-K
Material agreementNew debt8-K
Directors and officersShareholder vote8-K
Directors and officersResults announced8-K
Directors and officersResults announced8-K
Directors and officersResults announced8-K
Results announced8-K
Results announced8-K
Directors and officersShareholder vote8-K
Results announced8-K
Directors and officers8-K
Results announced8-K
Acquisition or sale completed8-K
Acquisition or sale completed8-K
Results announced8-K
Results announced8-K
Shareholder vote8-K
Directors and officersMaterial agreement8-K
Results announced8-K
Directors and officers8-K
Results announced8-K
Directors and officers8-K

Source: SEC EDGAR, Form 8-K item numbers · as of Nov 6, 2026

Lobbying by Anika Therapeutics, Inc.#

$0 spent on lobbying the US Congress and federal agencies in 2020.

Lobbying, 2020
$0
#1,364 among companies on value.today
Own lobbyists
No
only outside firms
Firms hired
1
in 2020
2026 so far
$30 K

Lobbying firms hired in 2020

King & Spalding LLP

Anika Therapeutics, Inc.: lobbying spending by year
YearSpendingOwn lobbyistsReports
2026 (so far)$30 K—1
2020$0—3
2019$0—4
2018$0—4

Source: Lobbying Disclosure Act reports (Form LD-2). Filed as “Anika Therapeutics, Inc.” and “Anika Therapeutics Inc”. Reports round to the nearest $10,000, and one of less than $5,000 counts as zero

H-1B hiring at Anika Therapeutics, Inc.#

2 labor condition applications certified in fiscal 2026 for 2 positions, at a median wage of $124 K a year.

Certified, FY2026
2
#1,538 among companies on value.today
Worker positions
2
Median wage offered
$124 K
a year, full-time
Applications filed
2
Anika Therapeutics, Inc.: most frequent H-1B job titles in fiscal 2026
Job titlePositionsMedian wage offered
Process Automation EngineerMechatronics Engineers1$113 K
Senior Process EngineerManufacturing Engineers1$134 K

Where: Bedford, MA 2

Anika Therapeutics, Inc.: labor condition applications by fiscal year
Fiscal yearCertifiedPositionsMedian wageFiled
FY202622$124 K2
FY202533$131 K3
FY202433$111 K3
FY202322$119 K2
FY202211$102 K1
FY202122$155 K4

Source: US Department of Labor, LCA disclosure data. An application is not a visa: USCIS decides each petition later, and the yearly lottery limits new H-1B visas. Filed as Anika Therapeutics, Inc.

Product recalls by Anika Therapeutics, Inc.#

1 recalls since 2015, 1,711 units in the notices that give a number. Medical devices (FDA): 1.

Anika Therapeutics, Inc.: product recalls
DateWhat and whyUnitsNotice
Hyalomatrix, Product nos. 651105, 651103, 651104, and 651301 Product Usage: Hyalomatrix is a bi-layered, sterile, flexible, and comfortable wound dressing that acts as an advanced wound care device. It is comprised of a non-woven pad entirely composed of HY AFF 11, a benzyl ester of hyaluronic acid, and a semipermeable silicone…Hyalomatrix products are susceptible to degradation as a result of the decomposition of PVC in the packaging material during sterilization, which resulted in degradation of the film. Over the long term it is possible that product integrity may be compromised.Medical devicesClass II1,711Z-2423-2018

Source: NHTSA, CPSC and FDA recall notices. Recalls filed under a subsidiary with a different name may be missing. The number of recalls says nothing about their seriousness

Layoffs at Anika Therapeutics, Inc.#

From US state WARN notices and SEC 8-K restructuring filings, newest first.

People, last 12 months
0
0 notices and filings
People, all years
12
2012–2012
Latest
12 people
2012-12-28
Anika Therapeutics, Inc.: people laid off by year and month
YearJanFebMarAprMayJunJulAugSepOctNovDecTotal
2012···········1212
Anika Therapeutics, Inc.: latest layoffs
AnnouncedPeopleKindWhereSource
12 peopleRestructuring planSEC 8-K“The plan adopted includes a reduction-in-force of 12 people and provides for severance payments, and the disposal of related supplies, equipment, and other assets.”Filing

Source: State WARN notices and SEC 8-K item 2.05

How Anika Therapeutics, Inc. compares in Biotechnology

  • Market cap$267 M · higher than 49% of 726
  • Revenue$113 M · higher than 70% of 647
  • Net margin-1.4% · higher than 70% of 408
  • Revenue growth-5.9% · higher than 37% of 438
  • Price / sales2.2× · lower than 83% of 339
  • Price / book1.9× · lower than 60% of 534
  • FCF yield1.6% · higher than 91% of 449

Peer comparison · Biotechnology

CompanyMarket capP/ENet marginRev. growth
Anika Therapeutics, Inc.🇺🇸$267 M—-1.4%-5.9%
Novo Nordisk A/S🇩🇰$203.2 B13.1×33.1%+10.8%
Vertex Pharmaceuticals Incorporated🇺🇸$134.3 B33.8×30.7%+8.9%
Moderna, Inc.🇺🇸$90.1 B—-110.5%-39.9%
Regeneron Pharmaceuticals, Inc.🇺🇸$84.1 B17.5×28.5%+1.0%
Argenx SE🇳🇱$52.8 B40.9×31.1%+89.9%
CSL Limited🇦🇺$51.6 B—-16.4%—
Samsung Biologics Co., Ltd.🇰🇷$51.5 B40.5×39.2%—
UCB SA🇧🇪$48.6 B26.3×20.1%+31.1%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Sep 30, 2026
Annual results:
For year ending December-2025
Balance sheet:
As of December-2025
Employees:
As on 2021
Profile updated:
Nov 20, 2026

Figures from Market data, SEC filing, value.today research, GLEIF register; financial statements from SEC filings.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at Anika Therapeutics, Inc.? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show Anika Therapeutics, Inc.'s ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about Anika Therapeutics, Inc.? Suggest a correction